EGFR联合TNF抑制在替莫唑胺耐药胶质母细胞瘤临床前模型中的疗效
该研究在原位小鼠胶质母细胞瘤模型中比较替莫唑胺与EGFR联合TNF抑制的疗效,涵盖MGMT甲基化、未甲基化原发、复发及实验诱导耐药亚组。结果显示两者在MGMT甲基化肿瘤中疗效相似,但在MGMT未甲基化、复发及耐药肿瘤中联合抑制更有效,且两方案靶向不重叠通路。
要点
- MGMT甲基化胶质母细胞瘤中替莫唑胺与EGFR联合TNF抑制疗效相似。
- MGMT未甲基化、复发及实验诱导耐替莫唑胺肿瘤中联合抑制更有效。
- 两方案靶向 distinct 且不重叠的通路,联合抑制可克服替莫唑胺耐药。
核心结论
- EGFR抑制联合阻断TNF驱动的适应性反应可能是MGMT未甲基化及复发EGFR表达胶质母细胞瘤的可行治疗策略。
研究设计与样本
- 研究采用原位小鼠胶质母细胞瘤模型,比较替莫唑胺与EGFR联合TNF抑制的疗效。
- 模型涵盖MGMT甲基化与未甲基化原发胶质母细胞瘤、复发胶质母细胞瘤及实验诱导替莫唑胺耐药胶质母细胞瘤多个亚组。
主要发现
- 在MGMT甲基化胶质母细胞瘤中,替莫唑胺与EGFR联合TNF抑制的疗效相似。
- 在MGMT未甲基化胶质母细胞瘤中,EGFR联合TNF抑制比替莫唑胺更有效。
- EGFR联合TNF抑制在替莫唑胺耐药的复发胶质母细胞瘤及实验诱导耐替莫唑胺的胶质母细胞瘤中仍保持有效。
- 两种治疗方法靶向不同且不重叠的通路。
临床怎么用
- 对于MGMT未甲基化或复发性EGFR表达胶质母细胞瘤,EGFR联合TNF抑制可能作为替莫唑胺耐药的替代策略。
局限性
- 研究基于原位小鼠临床前模型,结果尚未在人体临床试验中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glioblastoma (GBM) is the most common primary malignant adult brain tumor. Temozolomide (TMZ) is the standard of care and is most effective in GBMs that lack the DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT). Moreover, even initially responsive tumors develop a secondary resistance to TMZ and become untreatable. Since aberrant epidermal growth factor receptor (EGFR) signaling is widespread in GBM, EGFR inhibition has been tried in multiple clinical trials without success. We recently reported that inhibiting EGFR leads to increased secretion of tumor necrosis factor (TNF) and activation of a survival pathway in GBM. Here, we compare the efficacy of TMZ versus EGFR plus TNF inhibition in an orthotopic mouse model of GBM. METHODS: We use an orthotopic model to examine the efficacy of TMZ versus EGFR plus TNF inhibition in multiple subsets of GBMs, including MGMT methylated and unmethylated primary GBMs, recurrent GBMs, and GBMs rendered experimentally resistant to TMZ. RESULTS: The efficacy of the 2 treatments was similar in MGMT methylated GBMs. However, in MGMT unmethylated GBMs, a combination of EGFR plus TNF inhibition was more effective. We demonstrate that the 2 treatment approaches target distinct and non-overlapping pathways. Thus, importantly, EGFR plus TNF inhibition remains effective in TMZ-resistant recurrent GBMs and in GBMs rendered experimentally resistant to TMZ. CONCLUSION: EGFR inhibition combined with a blunting of the accompanying TNF-driven adaptive response could be a viable therapeutic approach in MGMT unmethylated and recurrent EGFR-expressing GBMs.
引用
- Guo G, Gong K, Puliyappadamba VT, et al. Efficacy of EGFR plus TNF inhibition in a preclinical model of temozolomide-resistant glioblastoma. Neuro Oncol. 2019. PMID: 31363754. doi:10.1093/neuonc/noz127
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。